Key Takeaways
- Steady execution, no surprises: Constant-currency revenue grew ~10.8% in H1, with management expecting a similar run-rate for the full year. Generic pricing pressure persists but volumes and customers are intact.
- Custom synthesis pipeline is deep, not yet commercial: High engagement, steady RFPs and site visits signal strong demand, but the next wave of commercial manufacturing is still 1 to 2 years out.
- Peptides are the strategic bet, and the company is all-in on CS: A new center of excellence is operational, multiple big-pharma projects are underway, and management has explicitly ruled out generic peptides to focus entirely on custom synthesis.
- Margins are stable but stuck: Gross margin held at ~60% as the shift to custom synthesis (now 56% of revenue) is offset by persistent pricing pressure on the 45% of business that is still generics.
- What to watch next quarter: Any movement on the three disclosed CS projects toward validation, the pace of Unit 3's GMP qualification, and whether generic pricing pressure eases from its current trajectory.
Custom Synthesis: The Next Growth Engine
- Pipeline depth, not breadth: Engagement levels are high with a steady flow of RFPs and site visits from global innovators. Multiple projects are advancing through development and validation, with a few expected to enter commercial manufacturing over the next 1 to 2 years.
- Three disclosed projects in motion: All three new projects disclosed to the exchange are in validation stages, at different phases of equipment installation, qualifications and validations. Revenue is expected in the next 1 to 2 years, contingent on regulatory approvals.
- Competitive moat is multi-dimensional: Management argues that MNCs select partners on EHS, sustainability, SBTi compliance and supply chain reliability, not just price and capacity. Divi's long-term customer relations and execution track record provide an edge that pure capacity cannot replicate.
- Old CS projects maturing: Products from custom synthesis engagements initiated 10 to 12 years ago have now matured, contributing to the current base while the next wave is being built.
Dr. Kiran S. Divi: "Pricing is one factor. Capacity is one factor. Divi's always is one step ahead in terms of capacity in terms of looking at forward, thinking in terms of creating capacity. But that is not the only thing. There are several factors you have to look at, unless you tick all the boxes, any multinational would not work with any firm."
Peptide Synthesis: The Focused Bet
- A 20-year foundation, now scaling: Divi's has been manufacturing protected amino acids for two decades, providing an edge in supply security, cost control and impurity profile management. New therapeutic categories have spiked innovator interest, and the company is engaged with several big pharmas across Phase I, II and III.
- CS-only, by design: Management has strategically decided not to pursue generic peptide synthesis, stating the company is fully occupied with the volume of custom synthesis projects it already has.
- Manufacturing scope is narrow and deep: Divi's manufactures mer fragments (tetramers, octamers, decamers) and its own Fmoc-protected amino acids, both natural and unnatural. It does not perform drug product purification, focusing instead on the high-value chemistry where its cost and impurity profile advantage is strongest.
- Center of excellence now operational: The newly inaugurated peptide center is spread across both existing units, not confined to one location, and is already hosting multiple customer projects under development.
Dr. Kiran S. Divi: "Divi has strategically decided that we will not look at generic part of peptide synthesis. We are right now fully occupied with the amount of CS projects we have. So, we do not want to venture into that mode."
Generic Business: Volume Resilience, Price Pain
- Volumes and customers are intact: The company has not lost a single customer or any production capacity. Key molecules like Naproxen, Dextromethorphan, Phenylephrine, Carbidopa and Levodopa have been very stable in pricing, with volumes steady year-on-year due to long-term contracts.
- Pricing pressure is the drag: Pricing pressures are increasing quarter-on-quarter, so stable volumes are not translating into revenue growth at the rate they would have 2 to 3 years ago. Management does not foresee any improvement for at least the next two quarters.
- Backward integration is the shield: The Unit 3 facility in Kakinada enables in-house production of starting materials and intermediates, supporting supply security and cost management. This provides an edge to retain products and volumes even as pricing erodes.
- Patent-expiry launches provide a growth driver: Products coming off patent that Divi's is launching with customers will provide a growth boost once those patents expire, offering a counterweight to the pricing headwind on the existing portfolio.
Margins: Stable but Constrained
- Gross margin held at ~60%: The metric was stable both YoY and QoQ for Q2 FY26, but varies with product mix quarter-on-quarter. The stability reflects a tug-of-war: custom synthesis now contributes 56% of revenue, but the remaining 45% in generics faces persistent pricing pressure, so combined margins look similar.
- No margin upside signaled: When asked whether 60% is a base case with upside risk, management would only say it would continue in a "similar manner." The shift toward custom synthesis has not yet lifted blended margins because generic pricing pressure is absorbing the benefit.
- New business margin is an unknown: Management declined to comment on whether new Phase III custom synthesis business carries higher margins, citing confidentiality agreements. Results will only be visible in the next 1 to 2 years once regulatory approvals are in place.
Capex & Capacity: Building Ahead of Demand
- Three major capex programs underway: All are backed by long-term supply commitments and focused on new technologies, capacity expansion and strategic projects. H1 spend was approximately ₹1,550 crores against an earlier ₹2,000 crores guidance, but management did not provide a revised full-year number, stating only that capex is ongoing and new projects are being evaluated.
- Unit 3 is operational but still ramping: Construction of six production blocks is complete. The unit is currently manufacturing starting materials and intermediates for in-house APIs and new projects. Transfer of products from Units 1 and 2 is ongoing, freeing up GMP-compliant capacity elsewhere. GMP qualification of in-house APIs and Drug Master File submissions are expected in the next few quarters.
- No reactive spending: Management emphasized that capex decisions are strategically planned and thought-through, not reactive to short-term opportunities. Capacity will be created as and when needed, spread across all three units.
- Asset turnover outlook is positive: In the next 1 to 2 years, management sees a positive outlook on asset turnover given the new opportunities in the pipeline.
Dr. Kiran S. Divi: "See, for us, nothing happens overnight. It's pretty strategically planned taken decisions which are thought through and where our strengths match. It's not like, okay, today, there's an opportunity, so let's jump on the bandwagon and go."
Contrast Media & Other Platforms
- Iodine-based contrast media progressing: The company is working on validations with three or four big global players, actively with one or two. This represents a new product category beyond the core generic and CS portfolios.
- Gadolinium compounds in development: Work is underway with several innovators on Phase III molecules. Even if a product is approved, the regulatory process across different countries will take at least one year before any revenue is visible.
- Technology platforms expanding: Divi's is expanding platforms in flow chemistry, biocatalysis and green chemistry, and has begun foraying into commercial manufacturing with all three.
- Nutraceutical segment evolving: The segment continues to develop as a growth driver, leveraging manufacturing strength in carotenoids and other value-added ingredients.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Constant-currency revenue growth | Around 10.79% for the full year, consistent with H1 run-rate | FY26 |
| Custom synthesis commercial manufacturing | A few projects in development/validation to enter commercial manufacturing | Next 1 to 2 years |
| Three disclosed CS projects revenue | Revenue to begin, provided all regulatory approvals are in place with no agency hurdles | Next 1 to 2 years |
| Generic pricing pressure | No improvement expected | At least next 2 quarters |
| Unit 3 GMP qualification | Submit Drug Master Files and obtain qualifications for in-house APIs | Next few quarters |
| Asset turnover | Positive outlook given new opportunities | Next 1 to 2 years |
| Gadolinium product revenue | Regulatory process across countries takes at least 1 year post-approval before any revenue | At least 1 year post-approval |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated total income | ₹2,860 cr, +17% YoY from ₹2,444 cr |
| Profit before tax | ₹912 cr, +26% YoY from ₹722 cr |
| Profit after tax | ₹689 cr, +35% YoY from ₹510 cr |
| Material consumption | 39.5% of sales revenue, consistent with recent trend |
| Forex gain | ₹63 cr |
| Constant currency revenue growth | 10.79% YoY |
| Exports share | 90% of total sales revenue |
| Europe and US export share | 74% combined of total sales revenue |
| Product mix (Generics / Custom Synthesis) | 44% / 56% |
| Nutraceutical revenue | ₹242 cr |
| H1 FY26 consolidated total income | ₹5,389 cr, +16% YoY from ₹4,640 cr |
| H1 FY26 profit before tax | ₹1,645 cr, +24% YoY from ₹1,326 cr |
| H1 FY26 material consumption | 39.6% of sales revenue, improved from 40.9% in H1 FY25 |
| H1 FY26 capex spend | ~₹1,550 cr, against FY26 guidance of ~₹2,000 cr |
| Generic business revenue growth (last 4 quarters) | ~7% (per an analyst's math) |